Personalizing Treatment Delivery
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Apr 6, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Personalizing Treatment Delivery," is focused on understanding how anxiety disorders and alcohol use problems often occur together. The researchers want to use new digital technology to identify specific factors that make some people more likely to have issues with alcohol when they also have anxiety or trauma-related symptoms. By gathering this information, they aim to create a personalized treatment plan that can help individuals seeking psychological support.
To participate in this study, you need to be between 18 and 65 years old, have access to a smartphone, and experience significant anxiety or trauma symptoms along with alcohol use problems. It's also important that you're interested in receiving counseling through telehealth (online). However, if you're currently receiving counseling or taking psychiatric medication that isn't stable, you may not be eligible. If you join the study, you can expect to engage with innovative tools that will help shape your treatment and improve your overall well-being. The trial is currently recruiting participants who live in New Jersey or New York.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Access to a smart phone
- • Between 18 and 65 years
- • Clinically significant anxiety or trauma-related symptoms
- • Alcohol use problems
- • Interest in telehealth counseling
- • Anticipated New Jersey or New York residence for the duration of the study
- Exclusion Criteria:
- • Currently receiving counseling
- • Psychiatric medication that is not currently at a stable dose (or is not anticipated to remain at a stable dose for the duration of the study)
- • Demonstrated indicators of more intensive or acute care
- • Temporary residence within the state of New Jersey or New York or out-of-state residence from the state of New Jersey or New York
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Piscataway, New Jersey, United States
Patients applied
Trial Officials
Marilyn Piccirillo, PhD
Principal Investigator
Rutgers Robert Wood Johnson Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported